

Freedom of Information request 015012

8/10/19

1 - How many melanoma patients undergoing treatment are BRAF+ ?

The Trust's Cancer Operations Manager has scanned through its Diagnosis and Pathology tables and is unable to locate a data field for BRAF+

It is believed that BRAF is an additional pathology test undertaken at University Hospital Birmingham UHB to identify mutations in particular tumours to focus chemotherapy treatments.

1a -In the past 3 months, how many melanoma patients were treated with the following:

Bevacizumab
Cobimetinib
Dabrafenib
Dabrafenib AND trametinib
Dacarbazine
Encorafenib AND binimetinib
Ipilimumab
Ipilimumab AND Nivolumab
Nivolumab
Pembrolizumab
Trametinib
Vemurafenib
Vemurafenib AND Cobimetinib
Other active systemic anti-cancer therapy
Palliative care

The Trust's Cancer Operations Manager has scanned through its Diagnosis and Pathology tables and is unable to locate a data field for BRAF+

The Pharmacy database does not identify drugs against patient disease. Information regarding individual patient treatment is held in individual patient records and not available from electronic reporting. Individual patient records are exempt from access under FOI exemption Section 40 Personal Information

1b - In the past 3 months how many patients were seen who had stage III resectable melanoma

As this question forms part of question 1 and 1a please see the responses to questions 1 and 1a

1c - Of all stage III patients seen, how many received a complete resection ?

As this question forms part of question 1, 1a and 1b please see the responses to questions 1, 1a and 1b

1d - Of all stage III patients seen, how many were stage III a ?

As this question forms part of question 1, 1a, 1b and 1c please see the responses to questions 1, 1a, 1b and 1c

2 - In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:

Afatinib

Atezolizumab monotherapy
Bevacizumab
Docetaxel monotherapy
Durvalumab
Erlotinib
Gemcitabine
Necitumumab
Nivolumab
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed
Ramucirumab
Vinorelbine and cisplatin / carboplatin
Other active systemic anti-cancer therapy [please state]
Palliative care only

The Pharmacy database does not identify drugs against patient disease. Information regarding individual patient treatment is held in individual patient records and not available from electronic reporting. Individual patient records are exempt from access under FOI exemption Section 40 Personal Information

3 - In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:

Afatinib
Alectinib
Atezolizumab mono
Atezolizumab + bevacizumab + carboplatin + paclitaxel
Bevacizumab
Brigatinib
Ceritinib
Crizotinib
Dacomitinib
Docetaxel monotherapy
Erlotinib
Gefitinib
Nintedanib with docetaxel
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed with carboplatin
Pemetrexed with cisplatin
Ramucirumab
Other active systemic anti-cancer therapy [please state]
Palliative care only

The Pharmacy database does not identify drugs against patient disease. Information regarding individual patient treatment is held in individual patient records and not available from electronic reporting. Individual patient records are exempt from access under FOI exemption Section 40 Personal Information.

4 - In the past 3 months, how many Urothelial cancer patients were treated with;

Atezolizumab
Carboplatinum in combination with another agent
Carboplatinum single agent
Cisplatinum in combination with another agent
Cisplatinum single agent
Nivolumab

Pembrolizumab

Any other chemo regimen without cisplatinum or carboplatinum

Other active systemic anti-cancer therapy [please state]

Palliative care only

The Pharmacy database does not identify drugs against patient disease. Information regarding individual patient treatment is held in individual patient records and not available from electronic reporting. Individual patient records are exempt from access under FOI exemption Section 40 Personal Information